Top Biotech Companies in Singapore (93)
Biomatch specializes in connecting top talent with leading companies in the life sciences sector, including pharmaceuticals, biotechnology, and medical technology. They offer tailored recruitment solutions, conduct candidate assessments, and aim to find the right job match for candidates and experts for companies.
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Learn...
ProfilePrint is an A.I.-driven predictive and prescriptive profiler, providing users with accessible, affordable, and portable solutions to ascertain and predict quality and profile of a food ingredient at the point of use, within seconds. Today, an enormous amount of resources are required to physically grade food samples across multiple stages of the global supply chain. ProfilePrint’s solution redefines transaction standards,...
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
Respiree© is a digital therapeutics company providing personalized healthcare services for chronic cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. The iRIS platform by Respiree© uses data captured from remote-patient-monitors, mobile applications and medical records to longitudinally measure, track disease progression and create reports for physicians and hospitals.
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
Kyberlife's technology arm holds the first open marketplace in Asia with an easy-to-use platform that hosts healthcare vendors, life-science companies & manufacturers globally. Kyberlife also has a distribution arm that facilitates licensed distribution of life-science/pharmaceutical/medical products, Instruments, equipment to the SEA region. Our vision is to provide for the millions of researchers in Asia, SEA & Australasia to shop for...
Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies.
Standard BioTools's Top Stability & Growth Strengths
Investor Backing & Capital Strength: The sale of the SomaLogic business to Illumina provided substantial cash proceeds, leaving the company with a strong cash and investment position to pursue M&A. Management cites enhanced balance sheet flexibility to support an inorganic growth strategy.
Cost & Operational Efficiency: Management has fully operationalized significant annualized cost savings and reduced operating expenses. Targets for positive adjusted EBITDA and adjusted cash flow by the end of 2026 indicate continued focus on efficiency.
Strong Market Position & Advantage: The company is widely recognized as a leader in mass cytometry and imaging mass cytometry through its CyTOF and Hyperion platforms. Ongoing platform updates and ecosystem signals point to durable leadership within these niches.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with...
Roche's Top Stability & Growth Strengths
Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.
Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.
Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
Founded in 2019, Virtue Diagnostics is an in vitro diagnostic provider committed to platform innovation in emerging markets. We have built a management team with decades of experience in the in vitro diagnostic industry and a global vision, coupled with robust R&D, operation and commercialization capabilities. We set up our industrialization bases in China, Brazil and Indonesia, and R&D centers...
CECO Environmental is a global leader in air quality and fluid handling serving the energy, industrial and other niche markets. Providing innovative technology and application expertise, CECO helps companies grow their business with safe, clean and more efficient solutions that help protect our shared environment. In regions around the world, CECO works to improve air quality, optimize the energy value...
Hoosier Cancer Research Network (HCRN) is an independent nonprofit contract research organization specializing in early-phase, multi-center, investigator-initiated oncology clinical trials, with a mission to advance cancer research, education, and patient advocacy.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
At KROSSLINKER, we innovate and transform Aerogel for challenging insulation applications. Our first product aims to serve the cold-chain biopharma packaging industry by protecting temperature-sensitive pharmaceuticals, precious biologics, and vaccines throughout their shipping journey with our transformative technology.
Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products...
AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the...
Avalere Health's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Revenue expanded in consecutive years, with double‑digit growth in 2023 followed by continued albeit slower growth in 2024. Trade coverage frames 2024 as a cooling market overall, suggesting the company’s trajectory reflects resilience amid a softer cycle.
Strong Market Position & Advantage: Industry rankings place the firm consistently in the MM+M Agency 100 top 20 in 2024–2025. External awards and frequent policy visibility reinforce stature in core North American healthcare‑agency and U.S. policy/access segments.
Future-Ready Strategy: Leadership additions, a unifying rebrand, and integration of advisory, medical, access, and marketing indicate a connected commercialization model. New offerings, AI/data‑driven tools, partnerships, and the “Every Patient Possible” mission signal preparation for evolving client needs.
Nutrition Technologies (“NT”) researches, manufactures and supplies sustainable agricultural inputs (animal feed ingredients, biofertilisers and biological agents). NT uses its unique proprietary biotechnology and Black Soldier Fly Larvae (BSFL) rearing process to recycle nutrients from agricultural and food processing by-products. Their insect-based products help feed the growing agriculture and feed industries around the world. These products are suitable for application...
Buckman is completely committed to helping our customers succeed, regardless of the challenges facing them, the industry they operate in or their location in the world. To fulfill that commitment, we surround our rigorously trained industry experts with the highest-quality chemicals, the latest smart technology and advanced data analysis. All focused on helping your operation improve productivity, increase profitability, and...
